Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [41] Metabolic syndrome in drug-naive Chinese patients with insulin-sensitive and insulin-resistant type 2 diabetes
    Lin, Jiunn-Diann
    Hseih, Chang-Hsun
    Lian, Wei-Cheng
    Pei, Dee
    Liang, Yao-Jen
    Chen, Yen-Lin
    ANNALS OF SAUDI MEDICINE, 2016, 36 (03) : 203 - 209
  • [42] Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naive Type 2 Diabetes Mellitus: A Randomized Controlled Trial
    Wu, Wenjun
    Li, Ying
    Chen, Xiong
    Lin, Dini
    Xiang, Songying
    Shen, Feixia
    Gu, Xuemei
    MEDICAL SCIENCE MONITOR, 2015, 21 : 2678 - 2684
  • [43] Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naive Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study
    Okajima, Fumitaka
    Sugihara, Hitoshi
    Emoto, Naoya
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2021, 88 (01) : 71 - 79
  • [44] Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study
    Tani, S.
    Nagao, K.
    Hirayama, A.
    DRUG RESEARCH, 2016, 66 (02) : 94 - 99
  • [45] Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes MellitusA Matching-Adjusted Indirect Comparison of Randomized Trials
    James E. Signorovitch
    Eric Q. Wu
    Elyse Swallow
    Evan Kantor
    Liangyi Fan
    Jean-Bernard Gruenberger
    Clinical Drug Investigation, 2011, 31 : 665 - 674
  • [46] Low Bone Turnover Associates With Lower Insulin Sensitivity in Newly Diagnosed Drug-Naive Persons With Type 2 Diabetes
    Nasser, Mohamad, I
    Stidsen, Jacob, V
    Hojlund, Kurt
    Nielsen, Jens Steen
    Eastell, Richard
    Frost, Morten
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (07): : E371 - E379
  • [47] Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
    Philis-Tsimikas, A.
    Del Prato, S.
    Satman, I.
    Bhargava, A.
    Dharmalingam, M.
    Skjoth, T. V.
    Rasmussen, S.
    Garber, A. J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08): : 760 - 766
  • [48] Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study
    Ujihara, Noriko
    Sakura, Hiroshi
    Hashimoto, Naotake
    Sasamoto, Kazuo
    Ohashi, Hiroshi
    Hasumi, Sumiko
    Kasahara, Tadasu
    Tomonaga, Osamu
    Nunome, Hideo
    Honda, Masashi
    Iwamoto, Yasuhiko
    DIABETOLOGY INTERNATIONAL, 2018, 9 (01) : 56 - 65
  • [49] The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
    Kodera, Ryo
    Shikata, Kenichi
    Nakamura, Akihiko
    Okazaki, Satoru
    Nagase, Ryo
    Nakatou, Tatsuaki
    Haisa, Shigeru
    Hida, Kazuyuki
    Miyashita, Katsuhiro
    Makino, Hirofumi
    INTERNAL MEDICINE, 2017, 56 (06) : 605 - 613
  • [50] Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study
    Pratley, R. E.
    Fleck, P.
    Wilson, C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (07): : 613 - 621